Home » FDA Clears Ranbaxy U.S. Subsidiary of cGMP Violations
FDA Clears Ranbaxy U.S. Subsidiary of cGMP Violations
Ranbaxy enjoyed some recent good news when its U.S. subsidiary resolved FDA current good manufacturing practice (cGMP) violations resulting from a 2012 inspection. The resolution came in the form of an establishment inspection report (EIR) to Ohm Laboratories, which manages Ranbaxy’s facility responsible for supplying a majority of the Indian drugmaker’s prescription and OTC products in the U.S. Ranbaxy’s Indian facilities remain under an FDA import alert.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
07May
-
14May
-
30May